Stock Ratings / Health Care / SCTX / insiders

ALEC (32) XFOR (35) AGEN (26) IRLA (32) ⌘ Pro Terminal →

Scribe Therapeutics Inc. (SCTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$17.44 -0.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Scribe Therapeutics Inc. (SCTX) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $330.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCTX)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SCTX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SCTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SCTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCTX)

✓Walkthrough of SCTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SCTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.07%▼ DESCENDING CHANNEL

2026-10-30O $17.00H $17.44L $14.77C $17.44VOL 479.2K

RES: $29.10SUP: $2.65SMA50: $24.10SMA200: $23.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCTX Butterfly Map → + Track SCTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SCTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SCTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCTX)

Health Care Rank #345 of 1016 ⚔️ ALEC vs SCTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCTX vs. ALEC, XFOR, AGEN, IRLA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Scribe Therapeutics Inc. (SCTX) ranks #345 by composite RQD confidence (50/100, grade D) and #509 by equity capitalization ($330.2M). Within this direct 5-issuer industry benchmark cohort, SCTX leads on earnings valuation at N/A trailing P/E, while ALEC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SCTX currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SCTX ACTIVE Scribe Therapeutics Inc.	D	50/100	—	—	—	-0.57%	$330.2M	Benchmark Subject
ALEC Alector Inc.	E	32/100	—	—	-35.0%	-0.44%	$332.1M	/alec-vs-sctx →
XFOR X4 Pharmaceuticals Inc.	D-	35/100	—	83.6%	-35.0%	+0.30%	$333.1M	/xfor-vs-sctx →
AGEN Agenus Inc.	E	26/100	—	96.0%	-35.0%	-0.56%	$320.2M	/agen-vs-sctx →
IRLA IRulya Therapeutics Inc.	E	32/100	—	—	-35.0%	-4.05%	$342.8M	/irla-vs-sctx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001853921

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scribe Therapeutics Inc. (SCTX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SCTX closed FY2025 with $78.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$78.2M	—

3. SCTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Scribe Therapeutics Inc. (NASDAQ: SCTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $17.44 (-0.57% 1D, market cap $330.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCTX ranks #345 in composite RQD confidence.

How does SCTX compare to ALEC and XFOR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCTX carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALEC (Alector Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $332.1M) and XFOR (X4 Pharmaceuticals Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $333.1M). Among the 5-stock peer group, SCTX leads on earnings multiple (N/A) while ALEC leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCTX?

Per SCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001853921), Scribe Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $78.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCTX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCTX last traded at $17.44 (-0.57% on volume of 252,928 shares), positioning the stock -27.63% below its 50-day simple moving average ($24.10) and -26.75% below its 200-day simple moving average ($23.81). Across its 52-week range of $13.50 to $39.60, SCTX sits at the 15.1% percentile with a 14-day RSI of 36.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($15.26 to $19.62).

SCTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are SCTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SCTX leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: SCTX RQD Cockpit SCTX 12M Forecast SCTX Earnings & Move SCTX Dividends & DRIP SCTX Insiders & 13F SCTX Whale Options SCTX Profit Sankey SCTX News & Why